Skip to Main Content

Author Details

Jennifer Alsop
University of Cambridge
2013
20
15
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36948887p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
34897700Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8<sup>+</sup> TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.J Pathol2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
32555365Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
31239549A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.Mod Pathol2019
29502561MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.Mayo Clin Proc2018
30062862Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.J Pathol Clin Res2018
28931370Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer.BMC Cancer2017
29049607Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.JAMA Oncol2017
28881617Germline whole exome sequencing and large-scale replication identifies <i>FANCM</i> as a likely high grade serous ovarian cancer susceptibility gene.Oncotarget2017
26261251Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.J Clin Oncol2015
26315354Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.J Natl Cancer Inst2015
24728189The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.Hum Mol Genet2014
25349970Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.Br J Cancer2014
23845225Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.Lancet Oncol2013
  • 1 - 20 of 20

Recommended Authors

Memorial Sloan Kettering Cancer Center
Career Start Year 2018
Number of shared co-authors 2
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 5
H. Lee Moffit Cancer Center and Research Institute
Career Start Year 2016
Number of shared co-authors 41
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 2
Oregon Health & Science University
Career Start Year 2013
Number of shared co-authors 75
Ontario Institute for Cancer Research
Career Start Year 2012
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 5
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 11
Boston University Chobanian & Avedisian School of Medicine
Career Start Year 2011
Number of shared co-authors 13
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
University of Basel
Career Start Year 2008
Number of shared co-authors 3
INSERM, Universite Clermont Auvergne
Career Start Year 2008
Number of shared co-authors 0
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 2
National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital
Career Start Year 2005
Number of shared co-authors 25
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 18
Peter MacCallum Cancer Centre
Career Start Year 2004
Number of shared co-authors 30
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 10
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Lund University
Career Start Year 2003
Number of shared co-authors 4
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 26
Olivia Newton-John Cancer Research Institute
Career Start Year 2002
Number of shared co-authors 3
Mayo Clinic
Career Start Year 2001
Number of shared co-authors 17
University of British Columbia
Career Start Year 2000
Number of shared co-authors 33
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 3
University of Southern California
Career Start Year 1995
Number of shared co-authors 9
University of Chicago
Career Start Year 1993
Number of shared co-authors 28
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 30
University of Pennsylvania School of Medicine
Career Start Year 1980
Number of shared co-authors 73
Yale University School of Medicine
Career Start Year 1980
Number of shared co-authors 9

Collaborators

University of Cambridge
Co-authored papers 19
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 19
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 19
Mayo Clinic College of Medicine
Co-authored papers 17
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 17
College of Nursing, University of South Florida
Co-authored papers 17
Cedars-Sinai Medical Center
Co-authored papers 16
Peter MacCallum Cancer Centre
Co-authored papers 16
Westmead Hospital
Co-authored papers 15
UCL EGA Institute for Women's Health, University College London
Co-authored papers 15
University of British Columbia
Co-authored papers 14
University of Calgary
Co-authored papers 14
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 13
University of British Columbia
Co-authored papers 12
University of New South Wales
Co-authored papers 12
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 12
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 12
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 11
Pomeranian Medical University
Co-authored papers 11
David Geffen School of Medicine, University of California los angeles
Co-authored papers 11
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 11
University of British Columbia
Co-authored papers 10
Eberhard Karls University Tubingen
Co-authored papers 10
Peter MacCallum Cancer Centre
Co-authored papers 10
Mayo Clinic
Co-authored papers 10
Alberta Health Services-Cancer Care
Co-authored papers 10
Otto-Friedrich-University Bamberg
Co-authored papers 10
The University of British Columbia
Co-authored papers 10
University of Alberta, Canada Cross Cancer Institute
Co-authored papers 10
John A. Burns School of Medicine, University of Hawaii
Co-authored papers 9